Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations
Pan Y, Hood A, Ahmad H, Altwerger G. Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. Annals Of Pharmacotherapy 2023, 57: 1162-1171. PMID: 36651235, PMCID: PMC11062080, DOI: 10.1177/10600280221149136.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBRCA1 ProteinBRCA2 ProteinCarcinoma, Ovarian EpithelialFemaleHomologous RecombinationHumansMutationOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsRetrospective StudiesConceptsRecurrent ovarian cancer patientsOvarian cancer patientsSomatic BRCA mutationsOverall response rateCancer patientsBRCA mutationsPARP inhibitorsStable diseaseResponse rateHR mutationsDuration of therapyDuration of treatmentSomatic BRCA1/2 mutationsPoly (ADP-ribose) polymerase (PARP) inhibitorsReal-world efficacyElectronic medical recordsHomologous recombination mutationsSomatic BRCAMedian TTPTreatment interruptionChart reviewRetrospective studyEfficacy analysisEntire cohortMajor trials